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Abstract
Nijmegen breakage syndrome (NBS) is a rare autosomal recessive syndrome of chromosomal instability mainly
characterized by microcephaly at birth, combined immunodeficiency and predisposition to malignancies. Due to a
founder mutation in the underlying NBN gene (c.657_661del5) the disease is encountered most frequently among
Slavic populations. The principal clinical manifestations of the syndrome are: microcephaly, present at birth and
progressive with age, dysmorphic facial features, mild growth retardation, mild-to-moderate intellectual disability,
and, in females, hypergonadotropic hypogonadism. Combined cellular and humoral immunodeficiency with
recurrent sinopulmonary infections, a strong predisposition to develop malignancies (predominantly of lymphoid
origin) and radiosensitivity are other integral manifestations of the syndrome. The NBN gene codes for nibrin
which, as part of a DNA repair complex, plays a critical nuclear role wherever double-stranded DNA ends occur,
either physiologically or as a result of mutagenic exposure. Laboratory findings include: (1) spontaneous
chromosomal breakage in peripheral T lymphocytes with rearrangements preferentially involving chromosomes 7
and 14, (2) sensitivity to ionizing radiation or radiomimetics as demonstrated in vitro by cytogenetic methods or by
colony survival assay, (3) radioresistant DNA synthesis, (4) biallelic hypomorphic mutations in the NBN gene, and (5)
absence of full-length nibrin protein. Microcephaly and immunodeficiency are common to DNA ligase IV deficiency
(LIG4 syndrome) and severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to
ionizing radiation due to NHEJ1 deficiency (NHEJ1 syndrome). In fact, NBS was most commonly confused with
Fanconi anaemia and LIG4 syndrome. Genetic counselling should inform parents of an affected child of the 25%
risk for further children to be affected. Prenatal molecular genetic diagnosis is possible if disease-causing mutations
in both alleles of the NBN gene are known. No specific therapy is available for NBS, however, hematopoietic stem
cell transplantation may be one option for some patients. Prognosis is generally poor due to the extremely high
rate of malignancies.
Zespół Nijmegen (Nijmegen breakage syndrome; NBS) jest rzadkim schorzeniem z wrodzoną niestabilnością
chromosomową dziedziczącym się w sposób autosomalny recesywny, charakteryzującym się przede wszystkim
wrodzonym małogłowiem, złożonymi niedoborami odporności i predyspozycją do rozwoju nowotworów.
Choroba występuje najczęściej w populacjach słowiańskich, w których uwarunkowana jest mutacją założycielską w
genie NBN (c.657_661del5). Do najważniejszych objawów zespołu zalicza się:m a łogłowie obecne od urodzenia i
postępujące z wiekiem, charakterystyczne cechy dysmorfii twarzy, opóźnienie wzrastania, niepełnosprawność
intelektualną w stopniu lekkim do umiarkowanego oraz hipogonadyzm hipogonadotropowy u dziewcząt. Na obraz
choroby składają się także: niedobór odporności komórkowej i humoralnej, który jest przyczyną nawracających
infekcji, znaczna predyspozycja do rozwoju nowotworów złośliwych (zwłaszcza układu chłonnego), a także
zwiększona wrażliwość na promieniowanie jonizujące. Wyniki badań laboratoryjnych wykazują: (1) spontaniczną
łamliwość chromosomów w limfocytach T krwi obwodowej, z preferencją do rearanżacji chromosomów 7 i 14, (2)
nadwrażliwość na promieniowanie jonizujące lub radiomimetyki, co można wykazać metodami in vitro, (3)
radiooporność syntezy DNA, (4) hipomorficzne mutacje na obu allelach genu NBN, oraz (5) brak w komórkach
pełnej cząsteczki białka, nibryny. Małogłowie i niedobór odporności występują także w zespole niedoboru ligazy IV
(LIG4) oraz w zespole niedoboru NHEJ1. Rodzice powinni otrzymać poradę genetyczną ze względu na wysokie
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reproduction in any medium, provided the original work is properly cited.ryzyko (25%) powtórzenia się choroby u kolejnego potomstwa. Możliwe jest zaproponowanie molekularnej
diagnostyki prenatalnej jeżeli znane są obie mutacje będące przyczyną choroby. Nie ma możliwości
zaproponowania specyficznej terapii, ale przeszczep szpiku możeb y ć alternatywą dla niektórych pacjentów.
Generalnie prognoza nie jest pomyślna z uwagi na wysokie ryzyko rozwoju nowotworu.
Keywords: Nijmegen breakage syndrome, Chromosomal instability, Immunodeficiency, Microcephaly, Predisposi-
tion to malignancy, Hypergonadotropic hypogonadism
Disease name and synonyms
Nijmegen breakage syndrome (NBS) (MIM #251260)
Ataxia-telangiectasia variant V1; AT-V1
Microcephaly with normal intelligence, immunodefi-
ciency, and lymphoreticular malignancies (Seemanova
syndrome II)
Immunodeficiency, microcephaly, and chromosomal
instability
Berlin breakage syndrome (BBS) (MIM #602667)
synonymous with #251260 Ataxia-telangiectasia variant
V2; AT-V2
A synonym given in MIM using the term “nonsyndro-
mal microcephaly” should not be used, as it is
misleading.
Definition
Nijmegen breakage syndrome is a rare autosomal reces-
sive disease presenting at birth with microcephaly but
generally no additional neurological manifestations.
Other important clinical features, more noticeable with
age, include mild growth delay, premature ovarian insuf-
ficiency, predisposition to recurrent infections of various
organs and a very high risk to develop malignancies at
an early age, most frequently of haematological origin.
Psychomotor development is usually not disturbed
despite progressive microcephaly, however, deterioration
of cognitive functions may occur with age. Combined
immunodeficiency of both the cellular and humoral
response is an essential feature of the disease. Chromo-
somal instability with characteristic rearrangements in
peripheral T lymphocytes in the form of inversions and
translocations involving chromosomes 7 and 14, and
cellular sensitivity to ionising radiation (IR) in vitro are
all characteristic for the disease and have diagnostic
relevance. Identifying mutations in both alleles of the
NBN gene (formerly NBS1) completes the diagnosis of
NBS.
Historical notes
The first description was in 1979 of a Dutch boy with
microcephaly, growth and developmental retardation,
IgA deficiency and chromosomal rearrangements
resembling those observed in ataxia telangiectasia (A-
T), i.e. affecting chromosomes 7 and 14 with break-
points in four sites (7p13, 7q35, 14q11 and 14q32) [1].
The discovery that a deceased brother of this patient
had presented with similar clinical features led in 1981
to the formal description of this genetic disease by
researchers at the University of Nijmegen in the Neth-
erlands, who named it, Nijmegen breakage syndrome
[2]. Patients manifesting microcephaly with normal
intelligence, immunodeficiency, and an unprecedent-
edly strong predisposition to lymphoreticular malig-
nancies were reported in 1985 as the Seemanova
Syndrome II [3] but it was subsequently confirmed
that they were actually affected with the same disease
[4].
In addition to chromosomal instability, intensive stu-
dies of NBS cells in vitro showed other cellular features
similar to those found in ataxia-telangiectasia, such as
sensitivity to IR and radioresistant DNA synthesis (RDS)
[4-6]. For these reasons, NBS was considered to be a
variant of A-T, even though the neurological symptoms
are clearly different and neither ataxia nor telangiectasia
are observed in NBS [7]. Complementation studies of
different NBS cell lines suggested genetic heterogeneity
and two groups were distinguished: A-T variant 1 (AT-
V1) or Nijmegen breakage syndrome and A-T variant 2
(AT-V2) or Berlin breakage syndrome [5,8].
In 1998 the gene responsible for NBS, originally desig-
nated as NBS1 but now renamed as NBN,w a sc l o n e d
and the gene product, nibrin, was identified [9-11].
Nibrin, together with MRE11 and RAD50 forms a tri-
meric protein complex (MRN) involved in repairing
DNA double strand breaks (DSBs). It became immedi-
ately apparent that mutations in the same gene were
responsible for both complementation groups, AT-V1
and AT-V2 [11].
Epidemiology
Nijmegen breakage syndrome is a rare disease and there
are no reliable estimates of its prevalence. The number
of known patients identified worldwide increased signifi-
cantly when the disease-causing gene, NBN,w a si d e n t i -
fied. Apart from over 150 subjects reported in the
medical literature [12-36], there are many more patients
recorded in national registries (e.g. Czech and Polish–
CKH p.c.). Currently, the largest European registry is
managed by the European Society for Immunodeficien-
cies (ESID).
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tinctly higher prevalence among Central European and
Eastern European populations, i.e. in the Czech Repub-
lic, Poland, Russia and Ukraine [3,6,31,34]. The propor-
tion of patients identified in these populations correlates
with a high carrier frequency of the major NBN muta-
tion, c.657_661del5 (p.K219fsX19), estimated to be 1
case per 177 newborns, clearly the result of a founder
effect [37]. Surprisingly, a similarly high frequency of
this mutation (1/176) has been found among newborns
in Northeast Bavaria, suggesting a relatively high pro-
portion of people of Slavic origin in that region [38].
Nijmegen breakage syndrome has also been reported
in many other European countries [2,8,14,23,36,39-42],
a sw e l la si nN o r t ha n dS o u t hA m e r i c a ,M o r o c c oa n d
New Zealand [12,15,22,27,32,35,43-46].
Clinical description
The clinical phenotype of NBS consists of several cardi-
nal features, such as progressive microcephaly, which
influences facial phenotype, mild growth delay, prema-
ture ovarian failure, cellular and humoral immunodefi-
ciency predisposing to recurrent infections, and an
exceptionally high risk of cancer development at an
early age.
Clinical manifestations described in detail below are
not exclusively specific for NBS, and can also vary in
severity.
Microcephaly and craniofacial features
A hallmark symptom of NBS is microcephaly, which is
observed from birth onwards and should alert a
neonatologist or a paediatrician [12,47,48]. Microcephaly
is defined as a reduction in occipitofrontal circumfer-
ence (OFC) to below -2 standard deviations (SD) from
the mean as compared to a healthy population of the
same age and sex. Microcephaly in NBS is progressive
and can be as severe as -9 SD in older children [49]. At
birth, the anterior fontanel is usually hardly palpable
and is closed within the first few weeks of life. Impor-
tantly, microcephaly can be masked by hydrocephaly,
until a ventriculo-peritoneal shunt is implanted [4,23,
CKH u.o.] or, exceptionally, by the presence of extre-
mely large subarachnoid cysts [50].
The dysmorphic facial features are very similar among
all patients with NBS and become more obvious with
age. The prominent midface is emphasized by the slop-
ing forehead and the receding mandible, which seems to
be secondary to the underdevelopment of the cranium
(Figure 1a, b). Other facial characteristics are more
subtle and diverse, i.e. palpebral fissures are upwardly
slanted in most patients, and the shape of the nose may
be both long and beaked as well as upturned with ante-
verted nostrils. In individual patients, cleft lip/palate or
choanal atresia have also been described [3].
Neurocognitive and intellectual development
Despite severe microcephaly, developmental milestones
are usually reached at normal times by the majority of
NBS children [3,6,8,12,41,47,48]. It is striking to observe
an infant or a toddler with severe microcephaly but with
no motor problems and with very good comprehension.
There are a few exceptions, such as a boy with schizen-
cephaly [44] and monozygotic twin brothers with
Figure 1 (a, b). Facial phenotype in NBS: face (a) and profile (b) of a girl aged 3.5 years. Note microcephaly, sloping forehead, small nose,
receding chin, and relatively large ears.
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the brain and severe epilepsy [28]. Psychomotor devel-
opment can be disturbed in individuals suffering from
very early onset and severe infections [2,23,51].
Delayed speech development is common, and speech
therapy is needed to correct articulation problems [CKH
u.o.]. Intelligence was shown to vary from normal to
mild or moderate mental retardation, but those reports
were based on single psychological evaluations
[2,3,12,40,41]. Long-term follow-up studies of a large
group of 48 Polish patients indicate that cognitive devel-
opment in NBS is a dynamic process: in early stages it
generally stays close to the average (normal or border-
line intelligence), but gradual deterioration is observed
during school-age years [CKH u.o.].
Growth pattern
The long-term study of over 70 Polish patients with
NBS allowed observation of growth patterns from birth
to adulthood, including puberty. Somatic development is
delayed from the beginning [52]. The mean birth
anthropometric parameters, including weight, length,
head and chest circumferences are significantly lower
than in a healthy population. Infants of both genders
show a growth deficit until the age of 2 or 3 years when
some gain of height and weight, but not OFC, is
observed. In later stages of childhood and adolescence,
differences in the growth pattern between the sexes
become apparent: the growth spurt in boys is poor and
is absent in girls. However, the adult mean height in
over half of the girls and the boys with NBS is within
lower normal ranges [52]. Thyroid and adrenal function,
concentration of insulin growth factor-1 were assessed
as normal and malnutrition syndromes were also
excluded in the Polish studies referred to here [CKH u.
o.].
Sexual maturation
There is clear sexual dimorphism among patients with
NBS in terms of pubertal development and concentra-
tions of gonadotropins, [39,43,53,54]. In Polish studies,
girls show no pubertal spurt and poor development of
secondary sex characteristics (Figure 2) accompanied by
low 17b-estradiol (E2) levels and high concentrations of
follicle-stimulating hormone (FSH) and luteinizing hor-
mone (LH) [53]. Moreover, gonadotropins showed a
biphasic pattern, with mean values within normal ranges
only in girls between 4 and 9 years of age, whereas in
all remaining age groups, FSH values were significantly
elevated, fulfilling the criteria of premature ovarian
insufficiency. Additionally, ultrasound visualised small
ovaries or solid streaks and a hypoplastic uterus [53]. In
contrast, puberty in boys with NBS is initiated sponta-
neously and progresses similarly to healthy peers [54].
So far, there have not been any reports of NBS patients
having offspring.
In contrast to the typical phenotype of NBS, it has
been reported that nonsense mutations of the NBN
gene can result in a far milder course of the disease
manifesting only as a fertility disturbance [55,56].
Congenital anomalies
Brain malformations
Small brain size, particularly with underdevelopment of
the frontal lobes, was found both intravital by MRI and
at autopsy [15,57,58]. In each case, the brain was half or
less than half the weight expected for age [3,59]. Com-
municating hydrocephalus has been diagnosed either at
birth [48, CKH u.o.] or shortly after [4], as well as at
autopsy in one patient and also after ultrasound on his
foetus-sibling [23]. Aplasia or hypoplasia of the corpus
callosum associated with colpocephaly and widening of
the temporal horns of the lateral ventricles are the other
most frequently reported anomalies of the central ner-
vous system (CNS) [15,31,57,58]. Neuronal migration
disorder (focal neuronal heterotopia) was documented
in single cases in the form of schizencephaly [44],
pachygyria [57] or partial lissencephaly [28]. On
Figure 2 Lack of breast development in a 16-year-old girl. Note
multiple pigmented nevi on the arm.
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of arachnoid cysts were found on CT or MRI [40,50,57].
Skeletal anomalies (minor)
Minor skeletal anomalies, such as clinodactyly of the 5
th
fingers and partial syndactyly of the 2
nd and 3
rd toes are
encountered in approximately half of the patients
[12,47].
Polydactyly, most frequently preaxial, occasionally also
postaxial, as well as a hypoplastic or absent thumb were
found in single cases [15,49], (Figure 3a, b). A radial
defect, especially of the reduction type is relatively fre-
quent in Fanconi anaemia (FA), another chromosomal
instability disorder [60]. Hip dysplasia was found in a
proportion of NBS patients [48], and single cases with
agenesis of one rib [15] or the sacral bone were also
described [48].
(b) Skin and hair
Café au lait spots and/or vitiligo spots are the most fre-
quently reported skin pigmentation anomalies observed
in approximately 50%-70% of patients [12,34,47-49]. In
three Polish patients, progressive depigmentation spread-
ing all over the body was observed [49]. Multiple pigmen-
ted nevi (Figure 2) are present in a proportion of patients
[39,45, CKH u.o.]; giant nevus was reported once [31].
In three patients, appearance of cutaneous, sarcoid-
like granulomatous lesions localised mainly on limbs
and face, which were refractory to treatment, preceded
diagnosis of diffuse large B-cell lymphoma (DLBCL) by
1-6 years [32,35,49].
Hair in NBS is usually thin and sparse in infancy and
early childhood but improves with age. Hair greying can
appear as early as in the second or third decade of life
[CKH u.o.].
Genito-urinary system and anal area
Congenital anomalies of kidneys such as renal hypopla-
sia/aplasia, the horseshoe or double kidney, ectopic/
dystopic kidneys are relatively frequent in NBS patients
[6,12,23,31,34]. These defects can also be associated
with urinary tract anomalies, such as duplication of the
renal pelvis and ureter or hydronephrosis [2-4] and pro-
mote infections in the urinary system, particularly in
patients with a defective immune defence.
Hypospadias, cryptorchidism, urethro-anal fistula were
also found [44,46, CKH u.o.].
Anal atresia or hypoplasia was noted in at least six
patients [8,31,61, CKH u.o.,].
Predisposition to malignancies
Patients with NBS have a high risk for developing malig-
nancy, the major cause of death in these individuals. Of
all the chromosomal instability syndromes, the incidence
of cancer in NBS patients is one of the highest.
By the age of 20 years, over 40% of NBS patients
develop a malignant disease, predominantly of lymphoid
origin. Non-Hodgkin lymphomas (NHL) of B and T
cells are the most common, predominantly diffuse large
B cell lymphoma (DLBCL), and T-cell lymphoblastic
lymphoma (TLBL), however, Burkitt and Burkitt-like
lymphomas are also encountered [62]. Data from the
Polish Registry of NBS patients indicate that the distri-
bution of lymphoma between B and T cell origins is
approximately even (45% and 55% respectively) [63].
Hodgkin disease, prolymphocytic leukaemia, acute lym-
phoblastic leukemia (ALL) with precursor B cells or T
cells, and acute myeloblastic leukemia (AML) have also
all been described [3,18,20,35,64, CKH u.o.]. An extre-
mely rare extranodal location of primary NHL has been
described in a 6-year-old boy with NBS who developed
pulmonary large B-cell NHL [17]. NHL arising in the
paravertebral region was diagnosed in two young adults
presenting with unexpected spastic paraplegia [CKH u.
o.].
Brain tumours such as medulloblastoma [65-67], and
rhabdomyosarcoma of extremely rare perianal localiza-
tion have been reported to develop more frequently in
Figure 3 (a, b). Hypoplastic and hypermobile thumb (a), and duplicated thumb (b).
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thyroid carcinoma, gonadoblastoma, glioma, menin-
gioma, neuroblastoma, and Ewing sarcoma were also
described [48].
An individual NBS patient treated for one cancer is at
an increased risk for developing different consecutive
malignant diseases of which lymphomas are the most
common [62,63]. Morphology, immunophenotype pro-
file and clonal Ig/TCR gene rearrangements performed
in 2 cases confirmed the de novo development of the
second lymphoma [64].
Haematological disorders
Aplastic anaemia (AA), a disease characteristic for FA
has been reported in at least three NBS patients of Sla-
vic origin [18,68]. In one case, bone marrow aplasia was
associated with EBV-related B-cell lymphoma [68].
Interestingly, Shimada et al. [69] reported a girl diag-
nosed with idiopathic severe AA at the age of 9, who
was mosaic with a majority of cells homozygous for the
NBN mutation I171V (c.511A < G; p.Ile171Val). The
girl had neither microcephaly nor immunodeficiency
characteristic of NBS.
Autoimmune complications such as haemolytic anae-
mia and a decrease in levels of the clotting factor V
related to T-cell prolymphocytic leukaemia (T-PLL)
were reported in a young adult with NBS [20].
Predisposition to infections
T h em a j o r i t yo fp a t i e n t ss u f f e rf r o mi n f e c t i o n so ft h e
respiratory tract, i.e. sinusitis, pneumonia and/or
bronchopneumonia that result in bronchiectasis in some
patients, and may even cause death due to respiratory
failure [2,3,6,8,31,34,42,51]. As a consequence of severe
frequent or persistent infections, in a few patients amy-
loidosis developed causing renal failure and death [18,
CKH u.o.]. Other relatively common infections are: otitis
media and mastoiditis, followed by urinary and gastroin-
testinal tract infections. Meningitis or encephalitis [23,
CKH u.o.] and cavernous thrombophlebitis restricted to
one hemisphere [16] were also observed in single cases.
In NBS patients, as in A-T, opportunistic infections
a r ev e r yr a r e[ 1 2 , 7 0 ] ,h o w e v e r ,p r o l o n g e do rr e p e a t e d
courses of antibiotic therapy may result in colonization
by Pseudomonas aeruginosa.O r a lCandida infections
have been observed in approximately one third of
patients in two large NBS groups followed for several
years [31,71].
Tuberculosis was reported in three cases: a generalized
type [18], a form restricted to the lungs and cervical
lymph nodes [34], and as a primarily cutaneous form
[36].
Viral infections, especially those caused by lymphotro-
pic and/or hepatotropic viruses (EBV, CMV, HBV,
HCV) may present a severe and chronic course, fre-
quently accompanied by lymphadenopathy, hepatosple-
nomegaly and/or pancytopenia which may mimic
lymphoma or leukaemia. Moreover, chronic viral stimu-
lation of defective cells may lead to monoclonal malig-
nancies such as B-cell and T-cell lymphomas [72,73]
On the another hand, there are also patients who,
despite confirmed immunodeficiency, do not suffer from
frequent infections and do not need immunoglobulin
supplementation until adulthood or development of a
malignancy [6,39,74, CKH u.o.].
Immunodeficiency
A longitudinal follow-up study of 70 NBS patients has
shown considerable variability in the immunodeficiency
observed among different NBS patients, as well as in the
same individual over the course of time. Systematic
monitoring of immune biomarkers has shown that dis-
turbances of the immune system are very heterogeneous
and can be profound, with a tendency to progress over
time.
Cellular immunity
T cell abnormalities
Immunological studies reveal mild or strong lympho-
and leucopaenia in nearly half of the patients with an
evident decrease of immunocompetent cells [75], T cell
immunity in NBS patients is characterized by a reduced
absolute number of CD3+ T cells in the vast majority of
patients, accompanied by a reduced number of CD4+
(helper) T cells (in about 90% of patients), with naive
CD4+ T cells expressing the CD45RA isoform signifi-
cantly decreased or practically absent. It is worth noting,
that in some NBS patients with normal total T cell
numbers, CD4+ T cell counts may be low [76]. The
number of CD8+ T cells can be normal, elevated or
markedly diminished, with a decreased ratio of CD4
+/CD8+ (< 1.0) being observed in over 70% of cases.
The number of natural killer (NK) cells (CD16+/CD56
+) varies from normal to significantly increased with
individual fluctuation evident over time [12,70,76,77]. In
the great majority of patients, a shift towards the mem-
ory phenotype of CD4+ T-lymphocytes expressing
CD45RO isoform is observed with a severe disruption of
the CD4+ naive cell/CD4+ memory cell ratio.
B cell abnormalities
The absolute number of B cells (CD19+, CD20+) is
reduced in 72%-75% of NBS patients and a normal
count is observed only in about 12%-18% [6,12,70,73].
In some patients, however, the absolute number of B
cells may be elevated even up to 1.4-2 times over the
upper limit for age, despite significant deficiency of
serum immunoglobulins and/or specific antibody
response [70]. This may indicate an intrinsic defect of
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[78-81].
Functional defects of lymphocytes
The in vitro proliferative response of T lymphocytes to
stimulation with phytohemagglutinin (PHA), anti-CD3
monoclonal antibodies and/or anti-TCR monoclonal
antibodies, as well as B cells to stimulation with conca-
navalin A (Con A) is greatly reduced in most NBS
patients [2,3,6,8,12,43,47,70,73,77,82,83]. In most studies,
delayed hypersensitivity skin tests were negative [8,84].
Humoral immunity
Total serum immunoglobulins
The humoral immunodeficiency in NBS patients is
highly variable and ranges from agammaglobulinemia to
a moderate reduction in the immune response. The
most characteristic feature of the humoral abnormalities
is deficiency of at least one or more immunoglobulin
isotypes (Igs). Severe hypogammaglobulinemia with IgG
< 2.0 g/l accompanied by a reduced concentration of
IgM and significantly decreased or undetectable levels of
IgA is found in 20%-24% of patients [12,43,70]. The
most commonly reported defects are IgG4 and/or IgG2
deficiency, followed by deficiency of total IgG and IgA
[6,12,70,73]. Although concentrations of total serum Igs
(IgM, IgG, IgA) are found to be normal in about 20% of
patients, it is worth noting that normal levels of total
IgG can mask deficiency of IgG subclasses, mainly IgG2
and/or IgG4.
Specific antibodies
Similar to total Igs, both normal [41,44] as well as dis-
turbed antibody responses to tetanus, Haemophilus
influenzae type B, diphtheria, polio and hepatitis B vac-
cination have been reported [8,21,51]. Naturally
acquired specific IgG antibodies to three pneumococcal
polysaccharides (serotypes 3, 19, 23) were found in only
25% of NBS patients investigated, while in all other
patients titres were undetectable or at a very low level.
This finding correlated with markedly decreased levels
of total IgG2. Similarly, most patients vaccinated against
HBV did not develop anti-HBs antibodies of a protective
IgG isotype or did not respond at all [26,70].
Monoclonal gammopathy and viral infections
One of the interesting findings in NBS patients were
elevated and/or gradually increasing concentrations of
total serum IgM [21,31,70,73,76], and these abnormal-
ities were frequently accompanied by monoclonal pro-
teins [70,82]. In a longitudinal study conducted on a
cohort of Polish NBS patients a high frequency (about
38%) of persistent monoclonal gammopathy of both
IgM (, l)a n d / o rI g G( , l) isotypes was observed.
However, it is important to notice that, in contrast to
IgM gammopathy, decreased or even very low concen-
trations of total serum IgG can mask the presence of
IgG gammopathy in these patients [73].
Genetic material of viruses with lymphotropic capacity
was found in nearly 68% of Polish NBS patients, with a
high prevalence of EBV infection (in 63% of patients)
accompanied by monoclonal gammopathy in most of
them. In some patients, HBV and/or HCV co-infection
was present and in four cases, CMV infection was found
[73].
Clonality of BCR/TCR gene rearrangements
Persistent clonal rearrangements of BCR and/or TCR
genes in peripheral blood lymphocytes were identified in
about 73% of NBS patients with, at the time, no clinical
signs of lymphoid malignancy. This phenomenon
showed evident progression over time in most patients
and was frequently accompanied by increasing viral
load, especially EBV, and preceded lymphoma diagnosis
by as much as 3 years [73].
Aetiopathogenesis
The most common hypomorphic mutation in NBN,t h e
gene responsible for NBS, is a five base pair deletion in
exon 6 which leads to two truncated fragments of
nibrin: the expected 26 kD amino-terminal fragment
(p26-nibrin), and, surprisingly, a 70 kD protein (p70-
nibrin) which is produced by a unique alternative initia-
tion of translation at a cryptic upstream start codon and
represents the carboxy-terminal portion of the protein
[85]. Null mutation of Nbn is embryonically lethal in
the mouse [86,87] but expression of the carboxyterminal
fragment, p70-nibrin, rescues both Nbn null mutant
cells in vitro and, indeed, mice in vivo [88,89].
Figure 4 shows the intron/exon structure of the NBN
gene and its product, nibrin. Nibrin protein forms a tri-
meric complex with MRE11 and RAD50 (the MRN com-
plex). In the amino-terminal portion of the protein, as
defined by the c.657_661del5 mutation, there is an FHA
domain and a BRCT domain, a second BRCT domain is
located downstream from c.657_661del5 [11,90]. Such
motifs are common in proteins which interact at phos-
phorylated residues and are frequently involved in cell
cycle regulation [91,92]. At the carboxy-terminal end are
domains required for association with the nuclease
MRE11 and the kinase ATM [9,93]. ATM is the gene
underlying A-T, a disorder with many features also found
in NBS. ATM is the primary activator of the cellular
response to DSBs and phosphorylates hundreds of target
proteins in response to IR, including nibrin [94,95]. IR-
induced phosphorylation of nibrin is further regulated by
the deacetylase, SIRT1, which keeps nibrin in the hypoace-
tylated state necessary for efficient phosphorylation [96].
The trimeric MRN complex is rapidly translocated to
the sites of DSBs after irradiation of cells and nibrin is
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sor of DNA DSBs and is required for the effective
monomerisation and autophosphorylation of ATM after
DNA DSB damage [97,98]. Clearly, this interaction
between nibrin and ATM explains the considerable phe-
notypic and cellular similarities between A-T and NBS.
The accumulation of MRN at damaged chromatin
requires the MDC1 protein with which it interacts via
the FHA domain of nibrin [99,100].
Nibrin is required not only for ATM activation but
also for phosphorylation by the kinase ATR [101]. ATR
(A-T and Rad 3-related) is activated by single-stranded
DNA generated during excision repair or at stalled repli-
cation forks. The ATR signalling pathway is particularly
sensitive to haploinsufficiency of genes implicated in its
regulation, for example, heterozygous deletion of RPA1
and RFC2 lead to impaired ATR signalling in response
to DNA damage [102].
The MRN complex is characteristically involved in both
the repair of DNA damage and the activation of cell cycle
checkpoints via ATM. Conditional Nbn null mutant fibro-
blasts are completely defective in the G2/M checkpoint
following treatment with the radiomimetic drug bleomycin
[88]. In the study by Difilippantonio and colleagues, mur-
ine B-cells with a conditional Nbn null mutation, and a
transgenic human NBN gene, with or without the
c.657_661del5 mutation, were examined. These Nbn null
mutants had defective G2/M-phase and intra-S-phase
checkpoints, comparable to those of ATM knockout cells
[89]. ATM downstream phosphorylation targets were
naturally also affected, with essentially no phosphorylation
of Smc1, CHK2 or Brca1 in response to IR.
The cell cycle defects in null mutant cells were par-
tially corrected by expression of the human NBN gene
with the c.657_661del5 mutation and fully corrected by
the wild type human gene. However, phosphorylation of
nibrin was not necessary for restoration of cell cycle
checkpoints [89]. In this connection it is noteworthy
that the NBN mutation c.643C > T (p.Arg215Trp) leads
to severe destabilisation of nibrin [28,103]. The level of
full-length nibrin drops to less than 20% and results in
strongly reduced activation of ATM [28].
Deficiencies in cell cycle checkpoints and disturbance
of cell proliferation are possibly significant for the
Figure 4 The NBN gene and nibrin. The exon structure of the gene is shown with the sites of mutations in NBS patients. The full length nibrin
protein, with an apparent molecular weight of 95 kDa and the two protein fragments arising from the c.657_661del5 mutation are shown. The
locations of serine residues targeted by the ATM kinase and acetylated lysine residues are indicated as are the relative locations of the FHA,
BRCT, Mre11-binding and ATM-interaction domains.
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s i ss e e m st ob ed i m i n i s h e dw h e nn i b r i ni sa b s e n to r
mutated. In two mouse models, disruption of the ATM
interaction site in nibrin led to a severe apoptotic defect
[104,105]. Since ATM is involved in IR-induced, p53-
dependent and p53-independent, apoptotic pathways
[106,107] the reduced apoptosis in the nibrin mutant
cells reflects a failure in the activation of ATM. A study
on human lymphoblastoid cell lines with different p53
status supports the view, that nibrin functions in IR-
induced apoptosis via its role in activating ATM [108].
Whilst the consequences for cell proliferation are less
clear, reduced clearance of heavily damaged cells is
surely a contributing factor to the increased cancer risk
in NBS [109].
Interestingly, p53 mediated apoptosis may play a role
in microcephaly, a cardinal feature of NBS. Mutation of
genes involved in neural proliferation is often associated
with microcephaly [110] and indeed, generation of null
mutation in Nbn specifically in developing neurons
resulted in disrupted cerebellum development [111].
However, the relevance of this finding for NBS patients
with a hypomorphic mutation of NBN remains to be
established. A further contributing factor to microce-
phaly in NBS may be the ATR signalling mentioned
above; microcephaly has been described as a general fea-
ture of defects in this pathway [102].
The deficiencies in immune response of NBS patients
and the DSB processing defect in their cells suggest that
immune gene rearrangements are inefficient in NBS.
Although a gross V(D)J recombination defect was
excluded [112,113], significant disturbances in the reso-
lution of RAG-induced IGH breaks and compensatory
proliferation of mature B cells have been recently
reported suggesting a more subtle V(D)J recombination
defect [114]. In addition, using conditional null mutant
mouse models it has also been shown that nibrin is
involved in immunoglobulin class switching [79,80].
After appropriate stimulation, less than 50% of null-
mutant B-lymphocytes were able to switch from IgM to
IgG1 or IgG3 [80]. In the humanized mouse model,
where human p70-nibrin is expressed in the absence of
murine nibrin, serum Igs showed a reduction of IgG1
and IgG3 isotypes reminiscent of NBS patients [89].
Furthermore, in B-cell and T-cell lymphomas isolated
from these mice, complex translocations involving the
IgH locus were found [89].
Mice heterozygous for an Nbn null mutation have a
significantly higher incidence of tumours, importantly,
in none of these tumours was the wild type allele lost
or inactivated [87]. This suggests that NBN is a hap-
loinsufficient tumour suppressor gene [115]. Indeed, it
has now been proven that heterozygous relatives of
NBS patients have a significantly increased cancer risk
[116]. A gene dosage effect has been recorded for
NBS patients too, with cancer occurrence lower in a
subgroup of patients with above average p70-nibrin
levels [117]. The individual variation in p70-nibrin
levels is thought to reflect differences in its proteolytic
turnover rather than differences in expression level
[118].
In addition to characteristic translocations, lymphocyte
chromosomes from A-T and NBS patients frequently
show end-to-end fusions indicating telomere dysfunc-
tion [75,119]. Accelerated telomere shortening has been
reported for both syndromes [120,121]. Data from mam-
malian cells suggest that one function of the MRN com-
plex at the telomere may be C-strand resection [122].
Disruption of the MRN complex or inhibition of ATM
led in normal telomerase-negative cells to telomere dys-
function [123]. Since telomere shortening triggers the
entry of cells into senescence, the role of nibrin in telo-
mere maintenance is likelyt ob eh i g h l yr e l e v a n tt o
growth retardation in NBS.
Diagnosis, diagnostic criteria and methods
Diagnosis and diagnostic criteria
Diagnosis of NBS is based on:
- characteristic clinical manifestations,
- chromosomal instability (spontaneous and
induced),
- increased cellular sensitivity to ionizing radiation in
vitro,
- combined immunodeficiency, cellular and humoral,
- mutations in both alleles of the NBN gene,
- complete absence of full length nibrin
Clinical criteria
Clinical diagnosis of NBS can be considered in children
of both sexes presenting with the following characteris-
tics:
a) Leading symptoms
- Microcephaly, usually present at birth,
- Recurrent respiratory tract infections
- Malignancies, especially of hematologic origin
(NHL, ALL), but also solid tumours
b) Additional criteria
- Characteristic facial phenotype (sloping fore-
head, prominent midface, receding mandible);
more evident with age,
- Mild growth retardation,
- Premature ovarian insufficiency
- General lack of neurological symptoms and
good psychomotor development,
- Cognitive development better in early child-
hood (normal or border-line intelligence) with
gradual decline.
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of NBS diagnosis if it indicates:
- sibling(s) with microcephaly or hydrocephaly,
- early deaths among siblings in the course of
severe/recurring infections or malignancy,
- other family members with malignancies.
Early diagnosis of NBS is very important in order to
avoid:
- severe recurrent infections, by employing appropri-
ate prophylaxis,
- unnecessary exposure to radiation for diagnostic
purposes,
- adverse reactions to radiotherapy for the treatment
of malignant tumours.
Diagnostic methods
The diagnosis of NBS is initially based on clinical mani-
festations and is confirmed by genetic analysis (Figure
5). Cytogenetics and molecular genetics can be utilized
for the final diagnosis, the order of use may depend on
the population origin of the patient. For Slavic popula-
tions, sequencing of exon 6 of the NBN gene is the
method of choice, since over 90% of these patients carry
the founder mutation c.657_661del5 on both alleles
[11,12,18,25,34,37]. In other populations, or when mole-
cular analysis is not possible, cytogenetic analysis could
be the diagnostic method of first choice. For this, karyo-
type analysis is necessary, comparative genomic hybridi-
sation is inappropriate [124,125].
Cytogenetic analysis
Spontaneous chromosomal instability
Cytogenetic analysis of standard PHA-stimulated periph-
eral blood lymphocytes (T cells) allows detection of
spontaneous chromosome instability, however, this may
be hampered by the poor response of NBS patient lym-
phocytes to mitogens [3,6,8,44,50,65].
The constitutional karyotype is generally normal, how-
ever, a broad spectrum of abnormalities can be observed
in 10-60% of cells. Among the aberrations most com-
monly found are open chromatid and chromosome
breaks, aneuploidies, marker chromosomes, partial
endoreduplication and structural rearrangements
[2-4,6,8,14,15,34,39-45,51].
Inversions and translocations, involving two different
loci in chromosomes 7 and 14 are particularly character-
istic for NBS and are found in the vast majority of cases
[28,51]. Significantly, the most frequently observed
breakpoints are located in chromosome bands 7p13,
7q35, 14q11, and 14q32, which are the sites of the T-
cell receptor genes (TCRG, TCRB, TCRA/D), and the
human immunoglobulin heavy chain gene (IGH),
respectively [126,127]. Such rearrangements are found
in 10-35% of metaphases in NBS patient T lymphocytes
[47] and in 5-10% metaphases in A-T [126,128], and
also to a lesser extent in ATLD (1-8%) [129,130] and in
NBSLD (1.5-4%) [131,132]. The most frequent aberra-
tion detected in NBS is inv(7)(p13;q35), followed by, in
order of decreasing frequency, t(7;14)(p13;q11), t(7;14)
(q35;q11), t(7;)(p13;q35) and t(14;14)(q11;q32) [6,42,47].
Other breakpoints in chromosomes 7 and 14 have been
observed [133]. In addition, Stumm et al. found an
increased frequency of other nonspecific translocations
in both NBS and A-T using a three-color chromosome
painting technique [133].
A few unusual cytogenetic cases have been reported.
Der Kaloustian et al. described a 5-year-old boy with
NBS and rhabdomyosarcoma in whom monosomies of
almost all chromosomes and triradial figures were found
in 64% and 16% of lymphocytes, respectively [44].
Recently Seemanova et al. [28] described severely
affected NBS monozygotic twin brothers who did not
present the hallmark feature of the disease, i.e. chromo-
somal instability. Neither chromosome breaks, nor
translocations, were increased, and no rearrangements
involving chromosomes 7 or 14 were found.
No increase of sister chromatid exchanges (SCE) was
found in lymphocytes from any NBS patient so far
investigated [2,8,39,43,44].
Chromosomal aberrations in lymphoblastoid cell lines
(LCLs, EBV transformed B lymphocytes) and in fibro-
blasts are different from those observed in T-cells.
Balanced and unbalanced translocations, isochromo-
somes, partial endoreduplications, aneuploidies, and
supernumerary marker chromosomes are frequently
found. Rearrangements of chromosomes 7/14, if present
at all, are in the form of telomere fusions [42,43].
Induced chromosomal instability
The frequency of chromatid and chromosome breaks
after treatment with IR or the radiomimetic drug bleo-
mycin is increased in the majority of tested NBS cell
lines as compared with normal reference cells, although
not as much as in A-T [4,8,15,41-43,45,74]. Enhanced
chromosomal breakage in lymphocytes/LCLs and fibro-
blasts clearly differentiates NBS cells from healthy cells
[49] however, in rare individual patients, no increase of
chromosome breakage was found [28,39].
Reaction to alkylating agents has been tested in cells
from some patients, but results are equivocal with
both insensitivity [43,44,48] and moderate hypersensi-
tivity [39,50,51,134-136] reported. A positive DEB test
contributed to misdiagnosis of NBS as FA in one
family, and as a consequence bone marrow transplan-
tation was performed. The patient was re-evaluated
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resulting in the final diagnosis of NBS [76]. The mole-
cular pathways of these two diseases clearly overlap
[135,137].
Radiation hypersensitivity and radioresistant DNA
synthesis
Assays based on other consequences of the characteris-
tic radiosensitivity of NBS cells, have been previously
Clinical diagnosis of NBS
Evaluation of 
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Mutation screening
exon 6 of the NBN gene
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Figure 5 Diagnostic flow-chart for NBS (see text for details).
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Page 11 of 19used to support diagnosis: the colony survival assay
(CSA) [45,138] and the radio resistant DNA synthesis
(RDS) assay [4,5,139]. The colony-forming ability of
NBS LCLs after exposure to IR or radiomimetics in
vitro is comparable to A-T cells and 2-4 times lower
than in control cells [5,45,138,140].
High levels of RDS have been shown in the vast
majority of NBS and A-T patients investigated
[4-6,44,140] and reflects their impaired S-phase check-
point [48]. After excluding mutations in the NBN gene,
confirmation of hypersensitivity to IR using CSA or
RDS assays strongly suggests evaluation for another
DNA repair disease, such as ligase IV deficiency (LIG4
syndrome), severe combined immunodeficiency with
microcephaly (NHEJ1 syndrome), NBS-like disease
(NBSLD), or ataxia telangiectasia like disease (ATLD)
[138].
Molecular diagnosis
Molecular testing provides conclusive verification of the
diagnosis. The majority of NBS patients identified to
date are homozygous for the NBN mutation
c.657_661del5 (p.K219fsX19): all but one patient in the
Czech Republic, Poland and Ukraine; the majority in
Russia; about 70% in the USA and many individual
cases in other countries all over the world
[11,14,18,21-23,27,30-32,34,35,141,142]. The remaining
patients are either compound heterozygotes of the
c.657del5 mutation and another unique mutation
[11,18,28] or carry a unique mutation in both alleles
[11,15,24,51,74,76]. All 11 known NBS-causing muta-
tions are in exons 6-10 of the NBN gene.
Two further mutations were identified in exon 4 and
10 in French siblings with infertility [56] and one homo-
zygous mutation in exon 5 in a Japanese child with AA
[69]. None of these individuals presented the clinical
features of NBS.
Testing strategy
Considering the frequency and spectrum of mutations,
the most effective approach is to begin with screening
for the founder mutation, c.657_661del5 (p.K219fsX19),
i ne x o n6o ft h eNBN gene. In populations with a high
frequency of this mutation [37] either Guthrie cards or
EDTA blood can be used. If the founder mutation is not
found or in only one allele, the next step is sequence
analysis of the remaining exons. In the case of failure to
identify a mutation or when the clinical diagnosis is
ambiguous, it is worthwhile to establish a LCL and
check whether nibrin is expressed by Western blot ana-
lysis. This testing strategy is shown schematically in Fig-
ure 5.
Western blot analysis
After generating a LCL, Western blot analysis allows
detection of the protein and assessment for correct size.
Finding full-length nibrin, after sequencing has shown
only a wild type sequence, excludes the diagnosis of
NBS. Testing sensitivity to IR in vitro is then advisable.
If the cell line is hypersensitive, evaluation for another
DNA repair disorder should be considered.
Differential diagnosis
With some exceptions, NBS is usually diagnosed in
childhood but rarely immediately after birth. Microce-
phaly, a hallmark feature of NBS, is a relatively frequent
sign, which is also present in several hundred other
inherited conditions as well as in many non-genetic dis-
eases, such as CMV infections.
A combination of microcephaly, growth retardation
and chromosomal instability links NBS with such dis-
eases as NBSLD, LIG4 syndrome, NHEJ1 syndrome, FA,
Seckel syndrome 1 and Bloom syndrome. Microcephaly
and immunodeficiency are common features in NBS,
LIG4 and NHEJ1 syndrome. Chromosomal anomalies
which are characteristic for NBS and A-T patients, such
as rearrangements between chromosomes 7 and 14 in T
cells, can also be elevated in NBSLD and ATLD.
On the other hand, considering only the combination
of chromosomal instability and immune deficiency, the
closest relationship is found between NBS and A-T.
T h e s et w od i s e a s e sa r ec a u s e db ym u t a t i o n si ng e n e s
coding for proteins cooperating in the same DNA repair
pathway, but presenting with distinct neurological mani-
festations [7].
The conditions most commonly confused with NBS
are FA [51] and LIG4 syndrome [143].
All diseases considered in the differential diagnosis are
inherited in an autosomal recessive manner and their
phenotypic overlap with NBS is presented in Table 1.
Genetic counselling
Parents of an affected child are obligate carriers of NBN
mutations. In each pregnancy there is a 25% risk that a
foetus will be affected. Siblings of a patient’s parents are
at 50% risk of being carriers. One exception to this rule
is a NBS patient homozygous for the mutation
c.657_661del5 in the NBN gene due to maternal isodis-
omy of chromosome 8 [30].
Heterozygous carriers of a NBN mutation do not pre-
sent with any symptoms. However, in some population
studies, a strong association with increased cancer risk
was found for carriers of the founder mutation,
c.657_661del5 [116,144-146]. This is of particular inter-
est for Slavic populations, where the population fre-
quency of the founder mutation is estimated at
approximately 1/177 [37]. Parents, being obligate car-
riers, should be offered monitoring for cancer.
Identifying the mutations in both alleles in an index
patient allows testing other family members at risk for
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population studies to recommend such testing in child-
hood (i.e. among proband’s sibs at risk).
Antenatal diagnosis
Families at a 25% risk of having an affected child may be
offered prenatal diagnosis if both disease-causing muta-
tions in the NBN gene are known. Molecular analysis is
the method of choice. Foetal DNA for molecular analy-
sis can be obtained either by chorionic villus sampling
(CVS) or by amniocentesis.
Management including treatment
No specific therapy is available for NBS. Due to the spe-
cific basic defect underlying immunodeficiency and sen-
sitivity to IR, patients with NBS require
multidisciplinary medical management and long term
follow-up. Specialised care provided by clinicians aware
of these problems and of the natural history of the dis-
ease can prevent some complications, avoid unnecessary
and excessive exposition to IR and take into considera-
tion the high risk for malignancy. MRI and ultrasound
examination are recommended as imaging techniques
rather than CT scan or X-ray.
It is important that patients with NBS are under the
care of one primary physician, preferably a paediatrician
or a general practitioner, who is acquainted with the
condition. Systematic (prophylactic) supervision by an
immunologist and oncologist is recommended. Female
patients should be under the care of an endocrinologist
and a gynaecologist when they reach pubertal age. Psy-
chological, social and educational support is essential for
improvement of the quality of patients’ life.
Assessment, care and treatment of immunodeficiency
Monitoring of the immune system is extremely impor-
tant throughout the whole life of a patient with NBS.
Generally, it is recommended that the primary care phy-
sician should refer the patient to an immunologist. The
immune biomarkers that should be evaluated in periph-
eral blood at the time of diagnosis and afterwards dur-
ing follow-up are listed below.
The evaluation of immunological profile at the time of
diagnosis:
Table 1 Disorders with chromosomal instability to be considered in the differential diagnosis of NBS
Condition MIM Gene Clinical features In vitro sensitivity to
damaging agents
NBS 251260 NBN
(NBS1)
Microcephaly, dysmorhic face, growth retardation (OFC more retarded than
height); reduced fertility
(hypergonadotropic hypogonadism in females); combined cellular and humoral
immunodeficiency
IR, Bleomycin; Alkylating
agents (MMC, DEB)–mild
NBSLD 604040 RAD50 Microcephaly, dysmorphic face, growth retardation (OFC more retarded than
height); mild spasticity, non-progressive ataxia; normal puberty; no
immunodeficiency
IR, Bleomycin
A-T 208900 ATM Progressive cerebellar ataxia, oculomotor apraxia, bulbar and skin telangiectasia;
(microcephaly only in exceptional cases); combined cellular and humoral
immunodeficiency
IR, Bleomycin; alkylating
agents (MMC, DEB)
-mild
ATLD 604391 MRE11 Microcephaly (in some); cerebellar ataxia (late onset/slow progressive);
oculomotor apraxia; no telangiectasia; no immunodeficiency
IR
DNA LIG4
syndrome
606593 DNA
LIG4
Microcephaly, dysmorhic face, growth retardation (OFC more retarded than
height); combined cellular and humoral immunodeficiency
IR, Bleomycin
NHEJ1 611291 NHEJ1 Microcephaly, dysmorhic facies, severe growth retardation; severe combined
cellular and humoral immunodeficiency
IR (variable)
FA 227650 FANC* Microcephaly (in some), growth retardation, skeletal abnormalities (radial defect);
reduced fertility (hypergonadotropic hypogonadism in males); pancytopenia
(progressive); no immunodeficiency
Alkylating agents (MMC,
DEB); IR (mild)
Seckel
syndrome 1
(ATR-SS)
210600 ATR Severe microcephaly, severe prenatal and postnatal growth retardation;
developmental delay, mental retardation; pancytopenia; no immunodeficiency
Alkylating agents (MMC); UV
(moderate)
BS 210900 BLM
(RECQL3)
Microcephaly, severe growth retardation (OFC retarded proportionally to height);
no specific immunodeficiency
UV
WBS 613398 DDX11 Microcephaly, prenatal and postnatal growth retardation, deafness; developmental
delay; no immunodeficiency
Alkylating agents (MMC)
A-T ataxia telangiectasia, ATLD ataxia telangiectasia like disease; ATR ataxia-telangiectasia and Rad3-related gene; BS Bloom syndrome; DEB diepoxybutane; DNA
LIG4 DNA Ligase IV; FA Fanconi anemia; IR ionizing radiation; MMC Mitomycin C; NBSLD NBS-like disease; NHEJ1 syndrome severe combined immunodeficiency;
OFC occipitofrontal circumference; WBS Warsaw breakage syndrome
*14 complementation group genes: FANC-A, -B, -C, -D1/BRCA2, -D2, -E, -F, -G, -I, -J, -L, -M, -N, -O (RAD51C)
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T-cell subpopulations (CD45RA, CD45RO), B-cells
(CD19+, CD20+), and NK-cells (CD16+ CD56+)
- function of T- and B-cells measured by prolifera-
tive response of lymphocytes to stimulation in vitro
with mitogens and/or antigens (e.g. PHA, anti-CD3,
anti-TCR, Covan A)
- concentration of total IgG, IgA, IgM and subclasses
of IgG
- C3 and C4 complement components
- monoclonal proteins
- EBV DNA load, HBsAg (alternatively HBV DNA),
HCV RNA (alternatively HCV RNA); the measure-
ment of specific antibodies in NBS patients is unsui-
table for diagnosis of virus infections
- BCR/TCR gene rearrangements in peripheral blood
lymphocytes
The assessment of immunological biomarkers during
control visits:
- absolute number of T-cells(CD3+, CD4+, CD8+)
and B-cells (CD19+, CD20+)
- concentration of total serum Ig’s
- monoclonal proteins
- EBV DNA load, HBsAg (if previously negative),
HCV RNA (if previously negative)
- BCR/TCR gene rearrangements in peripheral blood
lymphocytes
The assessment of immunological biomarkers should
be performed once a year in patients who are in good
clinical condition, and at 3-4 month intervals in patients
who manifest evident progression of the immune system
deterioration over time.
As in other combined immunodeficiency syndromes,
NBS patients generally need gamma-globulin replace-
ment therapy due to IgG deficiency. The overall consen-
sus among clinical immunologists is that an IVIG or
SCIG dose that maintains a serum IgG level over 5.0 g/l
(at least 4-6 g/l) is desirable [147]. SCIG infusion ther-
apy at home is an effective, convenient, and well toler-
ated alternative treatment modality, which gives
significant improvement in the quality of life [148]. It is
recommended that NBS patients should not be vacci-
nated with live bacterial or viral vaccines.
Assessment, care and treatment of malignancy
Symptoms of lymphoid malignancies in patients with
NBS and in the general population are usually similar
but in immunodeficient patients can be mistaken for
other conditions leading to fever, lymph node enlarge-
ment, loss of appetite and weight.
All diagnostic tests for lymphomas are the same as in
the general population, however, the pathological and
immunophenotypic picture may not always be charac-
teristic and this requires evaluation by an experienced
pathologist. In doubtful cases, classification may be
facilitated by using molecular cytogenetic techniques
[64,149,150]. This is crucial for the final diagnosis and
assigning patients to appropriate general treatment pro-
tocols [151,152]; there are no specific treatment proto-
cols designed for patients with lymphomas and NBS. It
has been noticed that disorders such as A-T and NBS
are associated with an increased risk for treatment-
related toxicity [13,153]. Treatment-related deaths
described in NBS patients are mainly from sepsis but
death due to early anthracycline-induced cardiomyopa-
thy was also reported [19].
Based on these observations it is common practice to
modify treatment for NBS patients by limiting the doses
of some chemotherapy agents (cyclophosphamide, ifos-
famide) and even avoiding others (epipodophyllotoxins).
The intensity of therapy is usually adapted to individual
risk factors and tolerance [13,21,29,153].
It is most likely that modification of treatment by low-
ering the doses or omitting some anticancer drugs
obscures final results. Administration of chemotherapy
with doses greater than 80% of prescribed drugs was
reported feasible and treatment related complications
manageable [62]. Relapse of NHL remains a major cause
of treatment failure [62,64].
There is new data emerging on successful treatment of
NBS patients with refractory or relapsed lymphoma with
hematopoietic stem cell transplantation (HSCT) [83].
Five out of 6 patients have restored T-cell immunity
and are alive with a median follow up of 2.2 years. This
suggests that HSCT should be considered for NBS
patients since they present with consecutive episodes of
lymphoma and correcting immunity may increase their
survival rate.
Children with NBS can develop malignant tumours
other than of lymphoid origin. Brain tumours in these
patients have been described (medulloblastoma, glioma).
Treatment of such patients should be restricted to che-
motherapy only as it was reported that CNS irradiation
resulted in radiotherapy-related death in 3 NBS patients
[65-67].
Follow up of growth and puberty
Endocrinological evaluation in NBS should include
anthropometric monitoring of growth from birth and
careful clinical evaluation of puberty in both sexes. Due
to the marked radiosensitivity in patients with NBS,
assessment of bone age based on hand and wrist roent-
genograms should be avoided. Premature ovarian
Chrzanowska et al. Orphanet Journal of Rare Diseases 2012, 7:13
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NBS, thus basal assays of plasma concentrations of FSH,
LH, and E2 in females reaching pubertal age are recom-
mended. Hormonal assays should be repeated in case of
initially normal results, as the pituitary-gonadal axis may
exhibit gradual dysfunction. Pelvic ultrasound is an aux-
iliary non-invasive examination, visualising the hypoplas-
tic uterus and ovaries. Female patients with delayed or
absent sexual maturation require the regular care of an
endocrinologist, gynaecologist, or both. When hypergo-
nadotropic hypogonadism is confirmed, replacement
hormone therapy to induce secondary sexual character-
istics, as well as to prevent osteoporosis, metabolic, car-
diovascular and psychosocial sequelae must be
considered when a patient reaches the appropriate age.
Despite normal puberty in NBS males, their sexual
development and gonadal function should also be super-
vised periodically, particularly since cases of cryptorchid-
ism and other anomalies of the genito-urinary system
have been previously described [44,46, CKH u.o.].
Psychologist/speech therapist
Delayed speech development is observed in many chil-
dren, and speech therapy is needed to correct articula-
tion problems.
Psychological assessment (IQ), before starting school
education and then periodically every few years to give
educational support is recommended because gradual
deterioration of intellectual skills with age is observed in
NBS individuals [CKH u.o.].
Prognosis
The prognosis for patients with NBS and malignancies is
unfortunately still poor. The largest series of 17 Polish
NBS patients with NHL indicates that a cure is possible
in individual patients and that the probability of survival
is better for those with B cell NHL rather than T cell
lymphoma. Thus, it is crucial to diagnose the disease as
early as possible. Monitoring of monoclonal gammopa-
thy, which in immunocompromised patients tends to
evolve to lymphoproliferative diseases, might be a useful
laboratory tool before serious complications of the dis-
ease develop. However, more data is required to confirm
the predictive value of monoclonal gammopathy moni-
toring for early lymphoma diagnosis. Hematopoietic
stem cell transplantation should be taken into consid-
eration for patients with NBS and NHL, since correction
of the immune system might help prevent further
malignancies.
Conclusions
Human diseases with deficiencies in DNA repair have
been extremely helpful in elucidating the networks
involved in the highly complex cellular response to
DNA damage. This has often led to a deeper under-
standing of the aetiology of the diseases and had conse-
quences for patient management, for example, in the
case of NBS, the recognition that therapeutic and diag-
nostic radiation is to be avoided at all costs. It is to be
hoped that further basic research will benefit patients
even more. For example, examination of the cellular
defect in patients with a particularly mild manifestation
of the disease could potentially lead to the development
of therapeutic strategies. Similarly, identification of mod-
ifying genes could help in prognosis and in optimizing
conventional therapy.
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